DALLAS, Dec. 15, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Novelos Therapeutics Inc. (OTCBB:NVLT). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
It is available at: http://www.beaconequity.com/i/NVLT
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Novelos Therapeutics Inc. (NVLT) is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the Company's lead compound, is in phase III development for treatment of lung cancer under a special protocol assessment and fast track. NOV-002 is also in phase II development for treatment of early-stage breast cancer and chemotherapy-resistant ovarian cancer. NOV-205, NVLTs' second compound, is in phase Ib development for chronic hepatitis C non responders.
Message Board Search for NVLT: http://www.boardcentral.com/boards/NVLT
In the report, the analyst notes:
"NVLT has financed its operations since inception through the sale of securities and the issuance of debt (which was subsequently paid off or converted into equity). As of September 30, 2009, the Company had $5,567,000 in cash and equivalents.
"NVLT announced in November that it will be presenting two scientific posters, based on collaborations with Drs. Kenneth Tew and Danyelle Townsend of the Medical University of South Carolina, Charleston, SC, and Drs. Alberto Montero and C. Marcela Diaz-Montero of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami, FL at the ongoing AACR-EORTC-NCI International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA. These presentations report findings in animal and cellular tumor model systems that add to the understanding of the pharmacological actions of NOV-002 and how these may relate to its clinical profile in oncology patients."
To read the entire report visit: http://www.beaconequity.com/i/NVLT
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that may fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.